Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Sign in
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Emerging Approaches in Schizophrenia
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
View All
Gerald Zernig, MD
JCP
Systematic Review
Therapeutic Reference Range for Olanzapine
July 19, 2023
A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
Katja Wesner
,
Christoph Hiemke
,
Niels Bergemann
, et al
JCP
Consensus Statement
Consensus on Monitoring Blood Antipsychotic Levels
May 19, 2020
The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
Georgios Schoretsanitis
,
John M. Kane
,
Christoph U. Correll
, et al
JCP
Original Research
Citalopram & Venlafaxine: Generic vs. Brand
July 21, 2009
Read a crossover study comparing of Pharmacokinetic Profiles of brand-name and generic Citalopram and Venlafaxine antidepressants.
Franck Chenu
,
Lisa A. Batten
,
Gerald Zernig
, et al
JCP
Article
St. John's Wort (Hypericum perforatum) and Breastfeeding: Plasma and Breast Milk Concentrations of Hyperforin for 5 Mothers and 2 Infants.
February 15, 2006
Claudia M. Klier
,
Brigitte Schmid-Siegel
,
Miriam R. Schäfer
, et al
